Instituto Medico Rio Cuarto | Research Center | Rio Cuarto, Argentina

Research site

(Unclaimed)

Location

Hipolito Irigoyen 1020, Rio Cuarto, Cordoba, Argentina

Site insights

Top conditions

Top treatments

Pembrolizumab

TAR-200

Rilematovir

Sotatercept

Vixarelimab

MK-7962-005

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 10 total trials

A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024) (LIGHTRAY)

Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harde...

Active, not recruiting

Pulmonary Arterial Hypertension

Biological: Sotatercept

Biological: Background PAH Therapy

A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) (SOTERIA)

This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in partici...

Active, not recruiting

PAH

Pulmonary Arterial Hypertension

Biological: Sotatercept

A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease

The main purpose of the study is to evaluate the efficacy of vixarelimab compared with placebo on lung function in participants with idiopathic pulmo...

Enrolling

Systemic Sclerosis With Lung Involvement

Idiopathic Pulmonary Fibrosis

Drug: Vixarelimab

Drug: Placebo

A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatme...

Active, not recruiting

Carcinoma, Squamous Cell, Non-small-cell Lung

Drug: Olaparib

Drug: Paclitaxel

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Active, not recruiting

Bladder Cancer

Biological: Cetrelimab

Drug: TAR-200

Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19 (NOVATION-1)

This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Nov...

Enrolling

Covid19

Biological: Placebo

Biological: Novaferon

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treat...

Active, not recruiting

Carcinoma, Nonsquamous Non-small-cell Lung

Drug: Carboplatin

Drug: Cisplatin

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms